The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Eryaspase for ALL: Results from the NOR-GRASPALL-2016 study
On April 6, 2022, results of the single arm, phase II NOR-GRASPALL 2016 study (NCT03267030) investigating eryaspase for the treatment of patients with acute lymphoblastic leukemia (ALL), were announced. The multinational study sought to evaluate the safety and asparaginase enzyme activity of eryaspase in patients who had suffered hypersensitivity reactions to prior pegylated asparaginase therapy; both objectives were met.1
When combined with chemotherapy, eryaspase demonstrated a favorable tolerability profile; two of the 55 enrolled patients withdrew treatment due to severe hypersensitivity reactions. Asparaginase enzyme activity exceeded the threshold (trough level, >100 U/L) 14 days after initial eryaspase infusion in 92.5% of patients.
Click here to access the results from the NOR-GRASPALL-2016 study as published by Lynggaard, et al., in the British Journal of Haematology.2
Eryaspase
Eryaspase is a donor-derived erythrocyte-encapsulated L-asparaginase product that targets asparagine and glutamine metabolism in cancer cells. Design rationale include prolonged half-life and reduced toxicity when compared with conventional asparaginase delivery methods.1
The U.S. Food and Drug Administration (FDA) granted Fast Track designation to eryaspase in July 2021 for the treatment of patients with ALL and pancreatic cancer who have experienced allergic reactions to E. coli-derived pegylated asparaginase.3 Eryaspase also received orphan drug status from both the FDA and European Medicines Agency (EMA) for the same indications.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content